What long-term trials show for Ozempic (semaglutide) and A1c?
Ozempic’s long-term A1c management is supported by multiple phase 3 trials that tracked A1c reduction over at least a year.
In SUSTAIN 1, the phase 3 program for once-weekly semaglutide, participants with type 2 diabetes receiving semaglutide achieved sustained A1c decreases over 30 and 56 weeks, depending on the study arm [1].
In SUSTAIN 3, semaglutide showed A1c reductions maintained through 56 weeks in adults whose baseline A1c was above target [2].
In SUSTAIN FORTE, designed specifically to compare 1.5 mg vs 0.5 mg doses, the trial measured A1c response through 40 weeks, supporting durable glycemic improvement across the higher-dose regimen [3].
How durable are the A1c effects in real-world-ish longer follow-up?
Beyond shorter controlled windows, the SUSTAIN trials collectively provide evidence of sustained glycemic control across 1-year time horizons for semaglutide dosing schedules that match Ozempic’s once-weekly administration. For patients starting with elevated baseline A1c, these studies reported clinically meaningful A1c declines that persisted through their longer follow-up periods [1][2][3].
Does semaglutide’s long-term A1c lowering link to complications or cardiovascular outcomes?
Ozempic’s long-term A1c benefit is also studied alongside major cardiovascular outcomes through long-duration trials. A widely cited example is SUSTAIN 6, which evaluated semaglutide over a longer period (median follow-up reported in the paper) for cardiovascular endpoints while also establishing that the glucose-lowering effect translated into sustained A1c improvements during the trial window [4].
That evidence is important because it suggests the drug’s glycemic effect is not just short-lived, though the primary objective of SUSTAIN 6 was not solely A1c reduction [4].
What happens to A1c when stopping or switching therapy?
The provided study citations focus on on-treatment trial periods, so the evidence here supports long-term A1c control during continued semaglutide use. The trials cited do not directly answer what A1c happens after discontinuation within the included sources.
If you want, tell me whether you’re asking about stopping Ozempic (and expected A1c rebound) or switching to another GLP-1/GIP therapy, and I can target that angle.
Sources
- https://pubmed.ncbi.nlm.nih.gov/26867501/
- https://pubmed.ncbi.nlm.nih.gov/26901238/
- https://pubmed.ncbi.nlm.nih.gov/34644358/
- https://pubmed.ncbi.nlm.nih.gov/27959765/